达利雷生片要求长期使用吗？

Introduction: Whether the tablet requires long-term use mainly depends on the patient's specific condition and the doctor's advice. Treatment for insomnia often needs to be tailored to individual circumstances, so long-term or short-term use is possible. It is important that patients follow the doctor's instructions, take medications on time, and have regular follow-up visits so that the doctor can evaluate the treatment effect and adjust the treatment plan.

The effects of Dalilaysan tablets

The new drug Dalilaysan was approved for marketing in the United States on January 7, 2022. A new drug marketing application was recently submitted in Japan and is undergoing Phase III clinical trials in China. The dual orexin receptor antagonists (DORAs) DaliRazen have no effect on sleep structure. A series of clinical trials have proven that DaliRasen has significant efficacy in patients with insomnia disorder, shortening the sleep onset latency, prolonging the total sleep time (sTST) and reducing awakenings after falling asleep.

Usage and Dosage of Dalilaysan Tablets

The recommended dosage of Dalilaysan Tablets is once a night, taken orally within 30 minutes before going to bed, the dosage range is between 25mg and 50mg, and it should be ensured that at least 7 hours remain before planned awakening. This medication arrangement helps the medication to work best before bedtime and improve sleep quality. It is worth noting that if taken with or shortly after a meal, it may cause a delay in falling asleep. Therefore, patients are advised to avoid taking it immediately after a meal to ensure that the drug is quickly absorbed and effective. When using Dalilaysan Tablets, patients should strictly follow the doctor's recommendations, pay attention to their own reactions, and consult their doctor in time if they have any discomfort.

Safety of use during the growth phase of Daliram

Clinical data on continuous treatment of Daliram for up to 12 months support that it can be used as a long-term medication option. The long-term use effect of DaliRasen was verified in the Phase III clinical trial of "The Lancet Neurology". The study showed that in the first and third months of treatment, DaliRasen significantly improved patients' falling asleep, sleep maintenance and total sleep time compared with placebo, without affecting sleep structure. In addition, the safety and tolerability of Dalitrazolin are good, with no occurrence of dependence, rebound insomnia, withdrawal symptoms or drug abuse, which is in sharp contrast to other common benzodiazepine receptor agonists.